TMCI
Treace Medical Concepts, Inc. NASDAQ Listed Apr 23, 2021$4.01
Pre-mkt
$3.86
-3.74%
Mkt Cap $253.7M
52w Low $1.20
43.2% of range
52w High $7.70
50d MA $2.72
200d MA $3.39
P/E (TTM)
—
EV/EBITDA
—
P/B
2.9x
Debt/Equity
0.2x
ROE
-67.6%
P/FCF
-8.6x
RSI (14)
57.70
ATR (14)
$0.37
Beta
0.88
50d MA
$2.72
200d MA
$3.39
Avg Volume
745.3K
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
203 Fort Wade Road · Ponte Vedra, FL 32081 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | AMC | -0.15 | -0.12 | +21.0% | 1.86 | -1.6% | -10.8% | -5.4% | -6.4% | -5.4% | +2.9% | — |
| Nov 6, 2025 | AMC | -0.28 | -0.26 | +7.1% | 6.23 | -37.4% | -28.3% | -20.4% | -5.6% | -0.9% | -5.7% | — |
| Aug 7, 2025 | AMC | -0.29 | -0.28 | +3.4% | 5.68 | -3.9% | +7.9% | +4.2% | +2.2% | +5.7% | +0.7% | — |
| May 8, 2025 | AMC | -0.31 | -0.25 | +19.4% | 7.54 | -9.8% | -9.5% | +5.6% | -3.1% | -3.7% | +0.4% | — |
| Feb 27, 2025 | AMC | -0.04 | -0.01 | +75.0% | 9.13 | -2.7% | -2.1% | -2.0% | +0.9% | +3.3% | -4.5% | — |
| Nov 5, 2024 | AMC | -0.27 | -0.25 | +7.4% | 5.76 | +25.0% | +35.1% | +1.5% | +1.8% | +3.1% | -3.0% | — |
| Aug 6, 2024 | AMC | -0.29 | -0.34 | -17.2% | 6.66 | -3.2% | -2.4% | -2.8% | -8.4% | -1.7% | +6.7% | — |
| May 7, 2024 | AMC | -0.30 | -0.30 | +0.0% | 11.12 | -59.5% | -62.5% | +6.2% | -1.1% | +3.4% | +10.4% | — |
| Feb 27, 2024 | AMC | -0.09 | -0.10 | -11.1% | 14.38 | -12.1% | -6.0% | -0.6% | -0.1% | +2.4% | -4.2% | — |
| Nov 9, 2023 | AMC | -0.26 | -0.28 | -7.7% | 10.00 | -47.3% | -37.9% | -2.9% | +20.9% | +9.1% | +5.0% | — |
| Aug 8, 2023 | AMC | -0.23 | -0.20 | +13.0% | 20.13 | -1.2% | -14.4% | -0.2% | -3.8% | +4.4% | +1.6% | — |
| May 8, 2023 | AMC | -0.23 | -0.23 | +0.0% | 25.97 | -18.4% | -3.7% | +4.5% | -1.1% | -2.7% | +2.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2 | Lake Street | Maintains | Buy → Buy | — | $1.86 | $1.83 | -1.6% | -10.8% | -5.4% | -6.4% | -5.4% | +2.9% |
| Jan 7 | Stifel | Maintains | Hold → Hold | — | $2.92 | $2.89 | -1.0% | -2.1% | +3.5% | -2.0% | -3.4% | -3.2% |
| Dec 18 | Truist | Maintains | Hold → Hold | — | $2.58 | $2.58 | +0.0% | -3.5% | +3.2% | -3.5% | -4.0% | +2.5% |
| Nov 10 | Truist | Maintains | Hold → Hold | — | $4.47 | $4.43 | -0.9% | -20.4% | -5.6% | -0.9% | -5.7% | -3.5% |
| Nov 7 | UBS | Maintains | Neutral → Neutral | — | $6.23 | $3.90 | -37.4% | -28.3% | -20.4% | -5.6% | -0.9% | -5.7% |
| Nov 7 | JP Morgan | Downgrade | Neutral → Underweight | — | $6.23 | $3.90 | -37.4% | -28.3% | -20.4% | -5.6% | -0.9% | -5.7% |
| Nov 7 | BTIG | Downgrade | Buy → Neutral | — | $6.23 | $3.90 | -37.4% | -28.3% | -20.4% | -5.6% | -0.9% | -5.7% |
| Oct 15 | Truist | Maintains | Hold → Hold | — | $6.20 | $6.20 | +0.0% | -1.3% | +4.2% | +0.9% | +5.6% | +2.2% |
| Sep 4 | Truist | Maintains | Hold → Hold | — | $7.25 | $7.32 | +1.0% | -1.1% | +0.0% | -0.8% | +4.1% | -5.4% |
| Aug 8 | Stifel | Maintains | Hold → Hold | — | $5.68 | $5.46 | -3.9% | +7.9% | +4.2% | +2.2% | +5.7% | +0.7% |
| Aug 8 | UBS | Maintains | Neutral → Neutral | — | $5.68 | $5.46 | -3.9% | +7.9% | +4.2% | +2.2% | +5.7% | +0.7% |
| May 9 | UBS | Maintains | Neutral → Neutral | — | $7.54 | $6.80 | -9.8% | -9.5% | +5.6% | -3.1% | -3.7% | +0.4% |
| Apr 11 | Truist | Maintains | Hold → Hold | — | $6.99 | $6.95 | -0.6% | -3.6% | +0.3% | -2.1% | -1.5% | -1.1% |
| Mar 13 | Truist | Maintains | Hold → Hold | — | $8.18 | $8.20 | +0.2% | -2.9% | +0.1% | +0.3% | +5.8% | -2.6% |
| Mar 3 | Truist | Maintains | Hold → Hold | — | $8.94 | $8.90 | -0.4% | -2.0% | +0.9% | +3.3% | -4.5% | -1.7% |
| Dec 18 | Truist | Maintains | Hold → Hold | — | $7.46 | $7.51 | +0.7% | -7.0% | -0.6% | +0.9% | +0.0% | +0.1% |
| Nov 6 | Stifel | Maintains | Hold → Hold | — | $5.76 | $7.20 | +25.0% | +35.1% | +1.5% | +1.8% | +3.1% | -3.0% |
| Oct 14 | Truist | Maintains | Hold → Hold | — | $5.26 | $5.21 | -1.0% | -1.1% | +2.3% | +0.9% | -1.5% | +0.9% |
| Aug 7 | UBS | Maintains | Neutral → Neutral | — | $6.66 | $6.45 | -3.2% | -2.4% | -2.8% | -8.4% | -1.7% | +6.7% |
| Aug 7 | Truist | Maintains | Hold → Hold | — | $6.66 | $6.45 | -3.2% | -2.4% | -2.8% | -8.4% | -1.7% | +6.7% |
| Jul 16 | Truist | Maintains | Hold → Hold | — | $8.22 | $8.30 | +1.0% | +2.8% | -0.1% | -6.5% | -0.1% | +0.9% |
| Jul 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.12 | $8.20 | +1.0% | +1.2% | +2.8% | -0.1% | -6.5% | -0.1% |
| May 16 | UBS | Downgrade | Buy → Neutral | — | $5.95 | $5.80 | -2.5% | -5.4% | -11.2% | -1.2% | +0.6% | +7.2% |
| May 8 | JP Morgan | Downgrade | Overweight → Neutral | — | $11.12 | $4.50 | -59.5% | -62.5% | +6.2% | -1.1% | +3.4% | +10.4% |
| May 8 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $11.12 | $4.50 | -59.5% | -62.5% | +6.2% | -1.1% | +3.4% | +10.4% |
| May 8 | BTIG | Downgrade | Buy → Neutral | — | $11.12 | $4.50 | -59.5% | -62.5% | +6.2% | -1.1% | +3.4% | +10.4% |
| May 8 | Truist | Downgrade | Buy → Hold | — | $11.12 | $4.50 | -59.5% | -62.5% | +6.2% | -1.1% | +3.4% | +10.4% |
| May 8 | Stifel | Downgrade | Buy → Hold | — | $11.12 | $4.50 | -59.5% | -62.5% | +6.2% | -1.1% | +3.4% | +10.4% |
| May 8 | UBS | Maintains | Buy → Buy | — | $11.12 | $4.50 | -59.5% | -62.5% | +6.2% | -1.1% | +3.4% | +10.4% |
| Dec 22 | Truist | Maintains | Buy → Buy | — | $11.88 | $12.45 | +4.8% | +2.1% | +4.6% | +1.3% | +0.2% | -1.0% |
| Nov 13 | Morgan Stanley | Maintains | Overweight → Overweight | — | $6.21 | $6.35 | +2.3% | -2.9% | +20.9% | +9.1% | +5.0% | +1.1% |
| Nov 10 | Stifel | Maintains | Buy → Buy | — | $10.00 | $5.27 | -47.3% | -37.9% | -2.9% | +20.9% | +9.1% | +5.0% |
| Nov 10 | Truist | Maintains | Buy → Buy | — | $10.00 | $5.27 | -47.3% | -37.9% | -2.9% | +20.9% | +9.1% | +5.0% |
| Oct 2 | Stifel | Maintains | Buy → Buy | — | $13.11 | $13.35 | +1.8% | -4.7% | +0.3% | -4.3% | +2.5% | -1.3% |
| Sep 12 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $14.20 | $14.20 | +0.0% | +7.2% | +2.2% | -1.7% | -5.9% | +0.9% |
| Aug 28 | BTIG | Maintains | Buy → Buy | — | $15.39 | $15.42 | +0.2% | +0.7% | +1.5% | +2.9% | -4.0% | +0.1% |
| Aug 10 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $17.24 | $17.28 | +0.2% | -0.2% | -3.8% | +4.4% | +1.6% | -3.8% |
| Aug 9 | Truist | Maintains | Buy → Buy | — | $20.13 | $19.89 | -1.2% | -14.4% | -0.2% | -3.8% | +4.4% | +1.6% |
| Jun 2 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $26.51 | $26.81 | +1.1% | +1.0% | -4.5% | +2.1% | +0.5% | -1.3% |
| Apr 17 | BTIG | Maintains | Buy → Buy | — | $24.74 | $24.57 | -0.7% | +4.4% | -1.9% | +2.1% | +1.5% | +0.9% |
| Mar 8 | Morgan Stanley | Maintains | Overweight → Overweight | — | $20.23 | $22.94 | +13.4% | +21.1% | +1.1% | -2.8% | -4.7% | +1.8% |
| Oct 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $21.90 | $21.96 | +0.3% | +2.1% | +2.5% | +0.3% | -2.5% | +2.9% |
| Sep 21 | Stifel | Maintains | Buy → Buy | — | $23.55 | $24.30 | +3.2% | -2.6% | -2.4% | +1.3% | -2.2% | +1.0% |
| Sep 21 | BTIG | Maintains | Buy → Buy | — | $23.55 | $24.30 | +3.2% | -2.6% | -2.4% | +1.3% | -2.2% | +1.0% |
| Aug 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $18.57 | $19.00 | +2.3% | +4.8% | -0.2% | +2.5% | +1.9% | -0.8% |
| Jul 18 | Stifel | Maintains | Buy → Buy | — | $16.27 | $16.41 | +0.9% | -5.2% | +3.4% | +1.1% | +0.1% | -3.1% |
| Jul 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $16.21 | $16.67 | +2.8% | +0.4% | -5.2% | +3.4% | +1.1% | +0.1% |
| May 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $16.32 | $15.96 | -2.2% | -19.4% | +1.2% | -2.9% | +5.3% | +7.1% |
| Mar 4 | Stifel | Maintains | Buy → Buy | — | $20.41 | $19.00 | -6.9% | +0.3% | -9.8% | +3.7% | +4.2% | -2.6% |
| Mar 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $20.41 | $19.00 | -6.9% | +0.3% | -9.8% | +3.7% | +4.2% | -2.6% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | Treace John T. | Chief Executive Officer | Buy | 9,891 | $4.04 | $40K | 7,348,439 | -3.45% | -4.30% |
| Jun 11, 2026 | Treace John T. | Chief Executive Officer | Buy | 22,887 | $4.04 | $93K | 7,376,150 | +3.84% | +4.49% |
| Jun 10, 2026 | Treace John T. | Chief Executive Officer | Buy | 14,715 | $4.02 | $59K | 7,338,548 | -3.45% | -4.30% |
| Jun 10, 2026 | Treace John T. | Chief Executive Officer | Buy | 29,430 | $4.02 | $118K | 7,353,263 | +3.84% | +4.49% |
| Jun 1, 2026 | Treace John T. | Chief Executive Officer | Buy | 50,000 | $3.56 | $178K | 7,323,833 | -3.61% | +0.57% |
| May 28, 2026 | Treace John T. | Chief Executive Officer | Buy | 61,202 | $3.02 | $185K | 7,273,833 | +12.34% | +8.53% |
| May 27, 2026 | Treace John T. | Chief Executive Officer | Buy | 49,810 | $2.87 | $143K | 7,212,631 | +12.34% | +8.53% |
| May 26, 2026 | Treace John T. | Chief Executive Officer | Buy | 4,508 | $2.79 | $13K | 7,162,821 | +12.34% | +8.53% |
| May 14, 2026 | Treace John T. | Chief Executive Officer | Buy | 61,750 | $2.62 | $161K | 7,158,313 | -3.97% | +0.71% |
| May 13, 2026 | Treace John T. | Chief Executive Officer | Buy | 49,013 | $2.46 | $121K | 7,096,563 | -3.97% | +0.71% |
| May 12, 2026 | Treace John T. | Chief Executive Officer | Buy | 43,000 | $2.17 | $93K | 7,047,550 | -3.97% | +0.71% |
8-K · 2.02
!! High
Treace Medical Concepts, Inc. -- 8-K 2.02: Earnings Results
Treace Medical Concepts reported quarterly earnings results showing its operational and financial performance, with details available in the attached press release for investor analysis.
May 8
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The departure of a key executive without dispute suggests an orderly transition, though investors should monitor leadership continuity and whether operations are disrupted during the handover period.
Apr 9
8-K
Treace Medical Concepts, Inc. -- 8-K Filing
Treace Medical Concepts reported its Q4 and full-year 2025 financial results, providing investors with updated performance metrics and guidance for the orthopedic medical device company's ongoing operations.
Feb 27
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Bank Of America Corp /de/ | 3,214,293 | $4M | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 1,461,507 | $2M | New | Mar 2026 |
| 3 | Cibc Bancorp Usa Inc. | 1,218,353 | $2M | New | Mar 2026 |
| 4 | Millennium Management | 1,148,115 | $2M | Reduced | Mar 2026 |
| 5 | Aqr Capital Management Llc | 1,061,840 | $1M | New | Mar 2026 |
| 6 | Acadian Asset Management Llc | 941,293 | $1M | Added | Mar 2026 |
| 7 | D.e. Shaw & Co | 841,269 | $1M | Added | Mar 2026 |
| 8 | Citadel Advisors Llc | 825,575 | $1M | Added | Mar 2026 |
| 9 | Morgan Stanley | 417,446 | $1M | Reduced | Dec 2025 |
| 10 | Weber Capital Management Llc /adv | 589,617 | $790K | — | Mar 2026 |
| 11 | Ubs Group Ag | 542,905 | $727K | Added | Mar 2026 |
| 12 | Wealth Enhancement Advisory Services, Llc | 242,411 | $708K | Reduced | Dec 2025 |
| 13 | Renaissance Technologies Llc | 522,900 | $701K | New | Mar 2026 |
| 14 | Vanguard Portfolio Management Llc | 435,893 | $584K | New | Mar 2026 |
| 15 | Northern Trust Corp | 405,903 | $544K | Added | Mar 2026 |
| 16 | Raymond James Financial Inc | 357,556 | $479K | Added | Mar 2026 |
| 17 | Jane Street Group, Llc | 177,008 | $434K | Added | Dec 2025 |
| 18 | Marshall Wace, Llp | 264,933 | $355K | New | Mar 2026 |
| 19 | Arcadia Wealth Management, Inc. | 209,972 | $281K | — | Mar 2026 |
| 20 | Nuveen, Llc | 153,755 | $206K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$253.7M
Enterprise Value
$219.3M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.79x
P/B
2.91x
P/S
1.22x
P/FCF
-8.60x
EV/EBITDA
—
Shares Out
63.3M
Financials (TTM)
Revenue
$207.3M
Net Income
-$61.0M
EBITDA
-$46.3M
Free Cash Flow
-$29.5M
Op Cash Flow
-$16.0M
EPS Basic
$-0.93
EPS Diluted
$-0.97
EPS Forward
$-0.91
Gross Margin
79.7%
Op Margin
-26.9%
Net Margin
-29.4%
Balance Sheet
Total Assets
$190.6M
Total Liab.
$103.2M
Total Equity
$87.3M
Cash
$48.4M
LT Debt
$14.0M
Book Value/Sh
$1.38
Debt/Equity
0.16x
Current Ratio
4.31
Quick Ratio
3.13
Returns & Growth
ROE
-67.6%
ROA
-31.0%
ROIC
-33.9%
Rev Growth YoY
+1.6%
EPS Growth YoY
-3.3%
Price Returns
2W
+24.9%
1M
+91.2%
3M
+86.0%
6M
+16.1%
12M
-39.7%
Technicals
52W High
$7.70
52W Low
$1.20
50d MA
$2.72
200d MA
$3.39
RSI (14)
57.70
ATR (14)
$0.37
Beta
0.88
Avg Volume
745K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$3.00
High
$3.00
Low
$3.00
Median
$3.00
Data updated apr 27, 2026 5:03am
· Source: financialmodelingprep.com